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Abstract Introduction: Since the pharmacological mode of action of botulinum
toxin (BTX) has been elucidated, its therapeutic potential has been increasingly
recognised. The aims of this review were to summarize our current understanding
of the pharmacological action of this agent and to review its therapeutic uses.
Methods: An electronic literature search with Medline (January 1965 to December
2004) was carried out to identify articles related to the pharmacological mode of
action and clinical uses for botulinum toxin using the keyword ‘‘botulinum toxin’’.
Results and conclusion: Botulinum toxin A is emerging as a valuable clinical tool,
both for diagnostic and therapeutic purposes in a wide variety of disorders, and is
already the treatment of choice for selected conditions. Better understanding of its
modes of action may identify alternative targets for pharmacological intervention,
and may allow development of longer acting drugs with lower immunogenicity.
Therapeutic uses of BTX-A must be assessed systematically in prospective studies,
and the clinical role of other subtypes requires evaluation.
ª 2005 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Background
Generalized paralysis with respiratory failure is the
principal mode of death in patients infected with
Clostridium botulinum, and is due to the systemic
neurotoxic effects of botulinum toxin (BTX) which
causes striated muscle paralysis.1 However, since
the pharmacological mode of action of BTX has
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doi:10.1016/j.ijsu.2005.06.005been elucidated,2 its potential for therapeutic use
in a wide spectrum of disorders associated with
muscle overactivity has become appreciated.3
BTX exists as seven antigenically distinct subtypes
(AeG), all of which are derived from C. botulinum,
but subtype A is the only toxin currently manufac-
tured for clinical use. BTX-A causes paralysis of
striated muscles by its effect on cholinergic neuro-
nes: the toxin binds selectively to presynaptic cho-
linergic nerve terminals via its heavy chain, and is
internalized by receptor-mediated endocytosis.4
The zinc-dependent light chain of BTX-A is thenlished by Elsevier Ltd. All rights reserved.
142 R.P. Sutcliffe et al.released into the cytoplasm,5 and cleaves SNAP-25,
a cytoplasmic synaptosome-associated protein that
is necessary for neurotransmitter release.6,7 Other
BTX subtypes have similar modes of action, subtypes
C and E also cleaving SNAP-25, and subtypes B, D and
F cleaving synaptobrevin, also involved in vesicle
release.2 More recently, an appreciation that BTX-A
inhibits glandular secretion and induces paralysis of
smooth muscle has resulted in a marked expansion of
its potential therapeutic applications.3 Although the
exact mechanisms by which BTX-A exerts its effects
on smooth muscle have not been fully evaluated, in
vitro work on internal anal sphincters suggests that it
may work by inhibiting noradrenaline release from
sympathetic neurones.8
Since being granted FDA approval for the treat-
ment of strabismus and blepharospasm in 1989,9
BTX-A has been used to treat disorders that are
characterized by overactivity of either (1) muscle
(striated or smooth), or (2) exocrine glands (e.g.
sweat and salivary) (see Table 1). A minute quantity
of BTX-A injected locally into either muscle or
glandular tissue causes neuromuscular blockade
or reduced glandular function without systemic
toxicity.3 Local side effects, including rash
or excessive neuromuscular blockade (e.g. faecalincontinence) are well recognised, while systemic
paralysis is rare.10 Although BTX-A causes irrevers-
ible blockade of neurotransmission, its clinical
effect is short-lived, with symptoms frequently
recurring after only a few months.11 This transient
effect of BTX-A has been attributed to expansion of
motor end plates, growth of collateral axonal
sprouts, and development of new neuromuscular
junctions.11 Failure of BTX-A therapy may also be
due to immunoresistance,12,13 the incidence of
which may be reduced by developing toxin
with lower immunogenicity.13 BTX-A may also
exert pharmacological effects on other aspects of
neuronal function, such as retrograde axonal trans-
port, motoneuronal excitability and presynaptic
inhibition,14 but their clinical relevance is un-
known.
Therapeutic uses
Neurology
Blepharospasm
BTX-A is first line treatment for this condition,
which is characterized by excessive involuntaryTable 1 Clinical uses of botulinum toxin
Site Condition
Head and neck
Smooth muscle Intraocular muscles Strabismus
Smooth muscle Levator palpebrae superioris Lid retraction
Striated muscle Orbicularis oculi Blepharospasm
Striated muscle Corrugator superciliaris Glabellar lines
Striated muscle Neck musculature Dystonias, whiplash
Smooth muscle Vocal cords Tourette’s syndrome
Gland Salivary glands Sialorrhoea
Striated muscle Cranial musculature Migraine
Striated muscle Lateral pterygoid Recurrent TMJ dislocation
Limbs
Striated muscle Upper and lower limbs Cerebral palsy
Gland Axilla Axillary hyperhidrosis
Gland Hands Palmar hyperhidrosis
Dystonia
Gastrointestinal tract
Smooth muscle Cricopharyngeus Cricopharyngeal dysphagia
Smooth muscle Lower oesophageal sphincter Achalasia
Diffuse oesophageal spasm
Smooth muscle Sphincter of Oddi Sphincter of Oddi dysfunction
Smooth muscle Internal anal sphincter Anal fissure
Anismus
Rectocoele
Urinary tract
Smooth muscle Detrusor muscle Detrusor instability
Detrusor-sphincter dyssynergia
Smooth muscle Internal urethral sphincter Detrusor-sphincter dyssynergia
Chronic prostatic pain
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BTX-A into the orbicularis oculi muscle are highly
effective, and are associated with less local
toxicity than doxorubicin chemomyectomy.16 Fail-
ure to respond to BTX-A injection may be due to
apraxia of lid opening, a condition that is effec-
tively treated by surgical myomectomy.17
Spasticity
BTX-A injection into lower limb musculature in
patients with cerebral palsy or after traumatic
brain injury significantly improves motor skill
performance, and may be a useful adjunct to
conventional treatments in the management of
lower limb spasticity in these patients.18e20 Early
data indicate that although muscle tone returns to
baseline after an initial reduction following BTX-A,
functional improvement of upper limb spasticity is
sustained.21 Improved results may be achieved by
using ultrasonography to guide BTX-A injections
into appropriate muscles.22
Dystonias
There is growing evidence that BTX-A is an effective
treatment for dystonias, including cervical dysto-
nia,23 myofascial pain,24 Piriformis syndrome25 and
writer’s cramp.26 BTX-A is more efficacious than
BTX-B for treating myofascial pain,24 and accurate
identification of muscles by electromyography ap-
pears to be important.23
Migraine
BTX-A has been used to treat migraine, and
although its mechanism of action is currently
unknown, symptomatic relief may be secondary
to its antinociceptive effect, rather than due to
neuromuscular blockade.27
Tourette’s syndrome
In a recent uncontrolled study of 30 patients with
Tourette’s syndrome and phonic tics, injection of
botulinum toxin into bilateral vocal cords im-
proved symptoms in 93%.28 This effect was sus-
tained for a mean duration of 102 days, and was
associated with an improved quality of life and no
serious side effects, although hypophonia devel-
oped in 80%.28
Parkinson’s disease
Anatomically guided injection of BTX-B into the
salivary glands is a safe and effective method of
reducing symptoms of sialorrhoea in patients with
Parkinson’s disease, and does not appear to sig-
nificantly worsen dysphagia.29Whiplash
The pathophysiology of whiplash, which is commonly
associated with motor vehicle accidents, is poorly
understood.30 Whiplash symptoms are thought to be
secondary to aberrant cervical muscle spasms, and
are treated either by physical therapies (e.g.
manipulation, transcutaneous electrical nerve
stimulation, ultraosonography and acupuncture)
or pharmacological agents (e.g. muscle relaxants
and nonsteroidal anti-inflammatory drugs). Prelim-
inary studies have indicated that botulinum toxin
injections may relieve pain and improve mobility in
patients suffering from whiplash,31 and results of
a prospective, randomized study are awaited.30
Cosmetic surgery
Facial rejuvenation
The effect of botulinum toxin to reduce dynamic
facial rhytids (wrinkles), such as glabellar lines, was
first observed in patients being treated for bleph-
arospasm. In a randomized, placebo-controlled
study, BTX-A injection into corrugator superciliaris
and/or procerus muscles was shown to significantly
reduce the severity of frown lines for up to 120
days,32 and FDA approval for its cosmetic use was
subsequently granted in 2002.
Gastroenterology
Achalasia
Achalasia is characterized by failure of lower
esophageal sphincter (LES) relaxation, typically
presents with progressive dysphagia, and has been
traditionally treated by either balloon dilatation or
surgical myotomy. Injection of BTX-A into the LES
provides symptomatic relief in 90% of patients,33
but due to its short-lived effect, recurrence of
symptoms is common, occurring in up to 70% of
patients within two years.34e37 Improved results
may be achieved by combining prograde and
retrograde injection of toxin into the LES, although
this must be confirmed in a randomized, controlled
study.38 Due to limited duration of response, BTX-A
is unlikely to supersede balloon dilatation or
surgical myotomy in the management of achalasia,
but provides a safe alternative in the elderly and
patients unfit for general anaesthesia.39 BTX-A has
also been applied to the treatment of diffuse
oesophageal spasm40 and cricopharyngeal dyspha-
gia41e43 although long-term benefits are unclear.
Sphincter of Oddi dysfunction
Injection of BTX-A into the sphincter of Oddi
in patients with post-cholecystectomy pain was
144 R.P. Sutcliffe et al.associated with relief of symptoms in more than
50% in one study,43 and potentially avoids morbid-
ity due to sphincterotomy.44 However, since its
effects last for less than 6 months, its clinical role
may be diagnostic, to aid selection of patients who
will benefit from sphincterotomy, rather than
therapeutic.39
Anal fissure
Up to one-third of patients will develop faecal
incontinence after surgical treatment of anal fis-
sures (anal stretch or lateral anal sphinctero-
tomy),45 while encouraging results with topical
nitroglycerin or calcium channel blockers have
prompted re-evaluation of most appropriate treat-
ment for this condition.46 A single injection of BTX-A
into the internal anal sphincter is effective, asso-
ciated with long-term benefit,47 and may be supe-
rior to topical nitroglycerin,48 although cost may
limit its availability.46 Recent in vitro data indicate
that BTX-A may cause sphincteric paralysis by
inhibition of sympathetic rather than parasympa-
thetic neurones,8 although this requires confirma-
tion in vivo.
Pelvic floor dysfunction
BTX-A injections may also relieve symptoms due to
anismus (inappropriate contraction of anal sphinc-
ter on straining), anterior rectocoele and follow-
ing surgery for Hirschsprung’s disease, although
direct comparisons with conventional approaches
are lacking, and the long-term benefits are un-
known.49e51 Long-term results may be improved by
using transrectal ultrasonography to direct injec-
tion of toxin.52
Ophthalmology
Strabismus
BTX-A may be used for both diagnostic and thera-
peutic purposes in patients with strabismus.53 After
transient monocular vision loss, BTX-A injection
permits selection of patients who have binocular
cooperation and may benefit from surgery.3 In-
jection of BTX-A into ipsilateral antagonist muscles
in patients with paralytic strabismus may prevent
muscle contracture.53
Dermatology
Hyperhidrosis
Focal hyperhidrosis, which is characterized by pro-
fuse and frequently disabling sweating, is due to
excessive secretion by eccrine sweat glands.54,55
Conventional treatments for hyperhidrosis haveimportant limitations, since unacceptable side ef-
fects develop commonly with oral anticholinergic
drugs54 and compensatory hyperhidrosis occurs in
the majority of patients after sympathectomy.56
Recently, BTX-A has been shown to be an effective
alternative for axillary hyperhidrosis,57 and although
it also appears to relieve palmar hyperhidrosis,58
injection of toxin at this site is painful, and may
cause nerve injury and impaired motor function.59,60
Facial flushing
Facial flushing, which is a common problem that
may be severe and disabling in some patients, has
been effectively treated by BTX-A in a patient
after failed laser treatment.61
Urology
Detrusor instability
Preliminary data indicate that intravesical injec-
tion of BTX-A in patients with neurogenic detrusor
instability is safe, improves bladder capacity and
reduces urge incontinence.62,63
Detrusor-sphincter dyssynergia
Transurethral or transperineal injection of BTX-A
effectively produces a sustained reduction in
external urethral sphincter pressure, voiding pres-
sure and post-void residual volume in patients with
multiple sclerosis and incomplete spinal cord
injury.64e67
Chronic prostatic pain
Injection of BTX-A into the external urethral
sphincter has been reported to improve chronic
prostatic pain, presumably by reducing sphincter
hyperactivity.68 Large prospective studies are re-
quired to clarify the role of BTX-A injections in
neuro-urologic disorders.
Miscellaneous conditions
Injection of BTX-A into the lateral pterygoid
muscle has been used to treat recurrent temporo-
mandibular joint dislocation with some success,69
while a sustained improvement of upper lid re-
traction due to dysthyroidism was demonstrated in
5 out of 6 patients in a recent study.70
Conclusions
Botulinum toxin A is emerging as a valuable clinical
tool, both for diagnostic and therapeutic purposes
in a wide variety of disorders, and is already the
Therapeutic uses for botulinum toxin 145treatment of choice for selected conditions. Care-
ful dosage, radiologic guided injection and re-
stricted use by appropriately trained individuals
are important in achieving clinical efficacy, and to
avoid local and systemic toxicity. Better under-
standing of the modes of action of botulinum toxin
A may identify alternative targets for pharmaco-
logical intervention, and may facilitate develop-
ment of neurotoxins with prolonged duration of
action and reduced immunogenicity. Therapeutic
applications of botulinum toxin A must be assessed
systematically in prospective studies, and the
clinical role of other subtypes requires evaluation.
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